- Ongoing, recruitingTherapeutic exploratory (Phase II)
EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures
This study is looking into new ways to treat advanced solid cancers. It's testing a combination of medicines (BI 907828 and Ezabenlimab) to see if they can help control the cancer's growth in adult patients. Researchers want to understand how well these drugs work.
For: Adult patients with locally advanced/metastatic solid tumorsFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
This study is testing a new drug for certain advanced cancers, including some pancreatic, lung, and bile duct cancers. Doctors want to see how well the drug shrinks tumours and if it's safe. It's for adults whose cancer has a specific genetic change.
For: Pancreatic ductal adenocarcinoma · Lung adenocarcinoma · Biliary tract adenocarcinomaSpain · France · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma
This study, called Brightline-4, is looking at a new drug, BI 907828, for advanced dedifferentiated liposarcoma. It aims to see how safe and effective the drug is for patients who haven't had treatment before or have had some treatment already. It's an important step to understand this new medicine.
For: dedifferentiated liposarcomaBelgium · Italy - Ongoing, recruitingPhase II and Phase III (Integrated)
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
This study is testing a new medicine, brigimadlin, for people with advanced dedifferentiated liposarcoma. It compares brigimadlin to a standard medicine, doxorubicin, to see if it can slow down or stop the cancer from growing.
For: Advanced dedifferentiated liposarcomaNetherlands · Belgium · Czechia